A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world

Previously, we have reported short term effectiveness and safety of dupilumab in Korea. In this study, we are trying to report the long-term effectiveness and safety of dupilumab in Korea. Ninety-nine patients with moderate to severe AD were analyzed. They were evaluated using Eczema Area and Severi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Dong Hyek, Heo, Seok Jae, Kook, Hyung Don, Lee, Dong Heon, Jung, Hye Jung, Park, Mi Yeon, Ahn, Jiyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651808/
https://www.ncbi.nlm.nih.gov/pubmed/34876623
http://dx.doi.org/10.1038/s41598-021-02950-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651808/
https://www.ncbi.nlm.nih.gov/pubmed/34876623
http://dx.doi.org/10.1038/s41598-021-02950-4

Ejemplares similares